BASF has joined forces with GEA Niro in cGMP spray drying for custom synthesis pharma production
Spray drying is an important technology to improve the bioavailability of poorly soluble APIs. The spray drying technology can be applied in pharmaceutical production to obtain several benefits including increased bioavailability, controlled release or taste masking, and to produce fine powders for inhalation or other applications. Through this alliance, BASF will add spray drying of APIs and formulations to its offerings as a provider of custom synthesis services for small molecules to the pharmaceutical industry.
By combining BASF’s state of the art custom synthesis capabilities and expertise in excipients with GEA Niro’s spray drying know-how and cGMP facilities, BASF has created a unique value proposition for its pharmaceutical customers.
Dr. Folker Ruchatz, BASF`s Director of Global Business Management Custom Synthesis: “BASF has already substantial know-how in spray drying. With this cooperation we add to our portfolio the ability to offer a cGMP facility. Teaming up with GEA Niro gives us access to a superior facility, and by working with the leading supplier of spray drying technology worldwide, we can provide the best solutions to our customers' needs sustainably.”
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.